ALK fusions with DCTN1 or other lysosome trafficking proteins may impair lysosomal traffic and maturation, promoting increased ALK signalling through perturbed lysosomal degradation, facilitating prostate cancer development. This evidence concerns the gene ALK and prostate carcinoma.